

Biofilm Formation And Quorum Sensing lasR Gene Of Pseudomonas Aeruginosa Isolated From Patients With Post-Operative Wound Infections

Marwa Fotouh Mahmoud¹, Fayza Mahmoud Fathy², Maha Kamal Gohar², Wael Mahmoud Awad⁴, Manar Hassan Soliman²

¹Microbiology and Immunology Department, Al-Ahrar Teaching Hospital, Zagazig, Egypt.

^{2,3,5}Medical Microbiology and Immunology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.

⁴General Surgery Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Corresponding Author:

Marwa Fotouh Mahmoud

M.B.B.CH., M.Sc., Faculty of Medicine- Zagazig University, Assistant Specialist of Microbiology & Immunology, Al-Ahrar Teaching Hospital, Zagazig, Egypt.

E-mail: marowa.fotouh@yahoo.com

ABSTRACT

Background: *Pseudomonas aeruginosa* (*P.aeruginosa*) is one of the most common bacteria capable of forming biofilms which are important in the establishment of *P. aeruginosa* infections on different host tissues including postoperative wounds. *P. aeruginosa* possesses at least two well-defined, interrelated QS systems, *las* and *rhl* that control the production of different virulence factors including biofilm development. **Objectives:** To determine the antimicrobial susceptibility pattern, biofilm producing ability and the presence of QS *lasR* gene in isolated *P. aeruginosa* strains from patients with post-operative wound infections. **Methodology:** The study was conducted on Fifty-four clinical isolates of *P. aeruginosa* from infected postoperative wounds in patients admitted in Zagazig university hospitals, Egypt. Isolates from all patients were tested for antimicrobial susceptibility using disk diffusion method, in vitro formation of biofilm in microtiter plates containing Tryptone Soya Broth (TSB) medium and detection of QS *lasR* gene using conventional PCR technique. **Results:** *P. aeruginosa* isolates showed high prevalence of resistance against ceftazidime and aztreonam (74.1%), while they showed the lowest resistance to ceftolozan/tazobactam (7.4%). Biofilm formation was detected in 38 (70.4%) of *P. aeruginosa* isolates; 14.8%, 46.3%, 9.3% and 29.6% of isolates were strong, moderate, weak and non-biofilm producers, respectively. The *lasR* gene was detected in 42 (77.8%) of *P. aeruginosa* isolates. There was significant relation between biofilm formation and presence of *lasR* gene. **Conclusion:** Postoperative wound infection may serve as a reservoir for multidrug resistant biofilm forming *P. aeruginosa*. The QS *lasR* gene is strongly associated with biofilm formation, which can help in identifying *lasR* gene as a useful diagnostic marker for biofilm producing *P. aeruginosa* strains isolated from infected wounds.

Key words: *Pseudomonas aeruginosa*, biofilm, *lasR* gene, wound infections

1. INTRODUCTION

Post-operative wound infections by multi-drug resistant (MDR) microorganisms are a global threat among the nosocomial infections leading to higher treatment expenditure, longer hospital stay, morbidity and mortality^{1,2}. As the skin constitute the first line of defense in human body, an injury to the skin can act as a portal of entry of pathogenic as well as opportunistic pathogens. The development of wound infection depends on the protective function of the skin which is a barrier of wound healing. Being most favorable site for biofilm formation, the wounds are considered as very high risk point for MDR microorganism infections. Post-operative wound infection is universal and the bacterial types present vary with geographic location, bacteria residing on the skin, clothing at the site of wound and time between wound and examination³. Generally, the most commonly isolated MDR microorganisms from wounds are *Pseudomonas aeruginosa* (*P. aeruginosa*), *Staphylococcus aureus*, *Escherichia coli*, *Acinetobacter spp.* and *Klebsiella pneumoniae*⁴. Though *P. aeruginosa* is an opportunistic pathogen, it is one of the most clinically significant organisms because of its multiple drug resistance properties, biofilm formation and production of several virulence factors such as exotoxin A, protease, leukocidin, lipopolysaccharide (LPS), phospholipase and other enzymes. The deadlines of *P. aeruginosa* is observed in post-operative wounds, burn wounds, chronic wounds and cystic fibrosis patients⁵. Biofilms are estimated to be responsible for over 65% of nosocomial infections⁶, and 60% of all human bacterial infections⁷. Bacterial biofilms may impair cutaneous wound healing and reduce topical antibacterial efficiency in treating infected skin wounds⁸. Biofilm formation occurs as a result of a sequence of events: microbial surface attachment, cell proliferation, matrix production and detachment⁹. *P. aeruginosa* is one of the most commonly studied bacteria capable of forming biofilms¹⁰. Biofilm formation is important in the establishment of *P. aeruginosa* infections on different host tissues^{11,12} as well as different medical devices¹³. In these settings, the antibiotic resistance engendered by biofilms presents a serious challenge to the treatment of chronic *P. aeruginosa* infections¹⁴.

Biofilm formation by *P. aeruginosa* involves the cell-to-cell communication quorum-sensing (QS) systems. QS is a cell-density-dependent mechanism through which bacteria coordinate different activities, including bioluminescence, plasmid conjugation and the production of different virulence factors^{11,15,16}. *P. aeruginosa* possesses two well-defined, interrelated QS systems, *las* and *rhl* that control the production of different virulence factors. Each QS system consists of two components, the autoinducer synthases (*lasI* and *rhlI*, respectively) and their cognate transcriptional regulators (*lasR* and *rhlR*, respectively). *LasI* is the synthase for the autoinducer N-(3-oxododecanoyl) homoserine lactone (3OC12-HSL), while *rhlI* synthesizes the autoinducer N-butyl homoserine lactone (C4-HSL)^{15,16}. The two QS systems of *P. aeruginosa* are hierarchically linked. The *las* system positively regulates the expression of *rhlR* and *rhlI*^{17,18,19}. *P. aeruginosa* also possesses an additional signaling molecule, 2-heptyl-3-hydroxy-4-quinolone (PQS). The production and activity of PQS is dependent on *lasR* and *rhlR*²⁰. It has been suggested that in *P. aeruginosa*, QS is involved in both the initiation of biofilm formation and the maturation of the biofilm. The *las* QS system appears to be especially important during the late stages of biofilm development²¹. This study aimed to determine the antimicrobial susceptibility pattern, biofilm producing ability, and the presence of Quorum sensing *lasR* gene in

isolated *Pseudomonas aeruginosa* strains from patients with post-operative wound infections at Zagazig University Hospitals, Egypt.

2. METHODOLOGY

Clinical isolates:

Fifty-four non repeat clinical isolates of *P. aeruginosa* were obtained from patients with post-operative infected wounds at Zagazig University Hospitals, Egypt. The isolates were collected within the period from December 2017 till March 2020. *P. aeruginosa* strains were isolated and identified based on standard microbiological techniques²².

Antimicrobial susceptibility testing:

Antibiotic susceptibility of all isolated strains was done by disc diffusion method (discs supplied by Oxoid, UK and Liofilchem, Italy), using Muller-Hinton agar plates (Oxoid, UK). After overnight incubation, results were reported and interpretation was done according to CLSI²³. ceftazidime, cefepime, aztreonam, levofloxacin, amikacin, imipenem, meropenem, ceftazidime/avibactam and ceftolozan/tazobactam were used for the antibiotic susceptibility testing.

Biofilm formation and quantification:

The tissue culture plate assay (TCP) is the most widely used and is considered as a standard test for detection of biofilm formation. The assay is based on the colorimetric measurements of the crystal violet incorporated by sessile cells²⁴. Overnight cultures of tested strains of *P. aeruginosa* were inoculated into 5 ml of trypticase soya broth (TSB) and incubated at 37°C for 24 hours. The turbidity was then adjusted to that of 0.5 McFarland standard. 200 µl of previously prepared suspensions were added to the wells of sterile 96-well flat bottomed polystyrene microtiter plates. Each strain was tested in triplicate (three wells per strain) and three wells in each plate were used as negative control (the negative control wells contain broth only: 200 µl of TSB), then the plates were covered with lids and incubated aerobically at 37°C for 24 hours. After incubation, the bacterial suspension of each well was gently removed. The wells were washed three times with 200 µl of phosphate buffered saline (PBS) to remove free-floating planktonic bacteria, and then the wells were air dried for 45 min. Adherence of bacteria to the culture plate was detected by crystal violet, in which 200 µl of (0.1%) crystal violet was added to each well and the plates were incubated at room temperature for 10 min. Excess stain was rinsed off by washing with deionized water (washed 3 times with 300 µl of water) and plates were kept for drying 20 min. After drying, 200 µl of 95% ethanol was added to the wells to solubilize the incorporated dye, the plate was covered with the lid (to minimize evaporation) and left at room temperature for 30 min. The optical densities (ODs) of the stained adherent bacteria were determined with a microplate reader at 600 nm. The average OD values were calculated for all tested isolates & negative control, the cut-off value (OD_c) was detected. It is defined as a 3 standard deviations (SD) above the mean OD of the negative control: OD_c = average OD of negative control + (3xSD of negative control). Final OD value of a tested strain was expressed as average OD value of the strain reduced by OD_c value (OD = average OD of a strain - OD_c); OD_c value was calculated for each plate separately. When a negative value was obtained, it was presented as zero, while any positive value indicated biofilm formation. Strains were divided into the following categories; non biofilm producers = OD ≤ OD_c, weak biofilm producers = OD_c < OD

$\leq 2 \times OD_c$, moderate biofilm producers = $2 \times OD_c < OD \leq 4 \times OD_c$ and strong biofilm producers = $4 \times OD_c < OD^{25}$ (figure 1).




Fig. 1: Microtiter plate showing different grades of biofilm formation.

PCR for detection of the quorumsensing lasR gene:

DNA was extracted from tested *P.aeruginosa* isolates, one colony of each strain cultured on solid medium was inoculated into 5 ml of TSB medium. After overnight incubation at 37°C; DNA was extracted from these cultures utilizing DNA extraction kit (Thermo Fisher Scientific, USA) according to manufacture instructions. PCR amplification was carried out using thermal cycler (Biometra, Germany) with specific primers for lasR gene²⁶ (table 1). PCR was performed in 25 μ l of reaction mixture containing 2 μ l of bacterial DNA template, 12.5 μ l Dream Taq PCR Master Mix (Thermo Fisher Scientific, USA), 100 pmol (1 μ l) of each primer and 8.5 μ l distilled water was added to bring the final volume to 25 μ l. PCR conditions were as follows: initial denaturation at 94°C for 1 min followed by 34 cycles of 94°C for 30 seconds, 50°C for 30 seconds and 72°C for 2 minutes, and a final extension at 72°C for 10 minutes²⁷. Agarose gel electrophoresis was used for examining the amplified products; PCR products were run on 2% agarose gel, stained with ethidium bromide visualized under UV transilluminator (Cole-Parmer, USA) and photographed²⁸.

Table 1: Primer sequence used in the study.

Gene	Primer direction	Primer sequence	Amplicon size (bp)
LasR	Forward	5' aagtggaaaattggagtggag3'	130
	Reverse	5'gtagtgccgacgacgatgaag 3'	

Statistical analysis:

Data were analysed using SPSS, version 25 (SPSS Inc., Chicago, IL) using Descriptive statistics and Chi-square test. Descriptive statistics including number and percentage for qualitative variables and mean and standard deviation for quantitative one. Chi-square test was used for analysis of qualitative variables and P-values were calculated. A P-value <0.05 was considered as statistically significant.

3. RESULTS

This study was conducted on fifty four clinical isolates of *P.aeruginosa* from post-operative wound infected patients admitted in Zagazig University Hospitals, Egypt in the period from December 2017 till March 2020.

Antibiotic susceptibility of *P. aeruginosa* isolates:

P. aeruginosa isolates showed high prevalence of resistance against ceftazidime and aztreonam 40 strains (74.1%) and 31 (57.4%) strains were resistant to cefepime, while 25 (46.3%) strains were resistant to levofloxacin, 17 (31.5%) strains were resistant to amikacin, 16 (29.6%) strains were resistant to imipenem, 12 (22.2%) strains were resistant to meropenem, 5 (9.3%) strains were resistant to ceftazidime/avibactam and 4 (7.4%) strains were resistant to ceftolozan/tazobactam (table 2). 41 (76 %) of *P. aeruginosa* isolates were MDR (figure 2).

Table 2: Antibiotic susceptibility results of *P. aeruginosa* isolates.

Antimicrobial agent	Concentration (µg)	Rssistant No. (%)	Intermediate No. (%)	Sensitive No. (%)
Cephems				
Ceftazidime	30 µg	40 (74.1%)	3 (5.6%)	11 (20.4%)
Cefepime	30 µg	31 (57.4%)	9 (16.7%)	14 (25.9%)
Monobactams				
Aztreonam	30 µg	40 (74.1%)	0 (0)	14 (25.9%)
Fluoroquinolones				
Levofloxacin	5 µg	25 (46.3%)	3 (5.6%)	26 (48.1%)
Aminoglycosides				
Amikacin	30 µg	17 (31.5%)	0 (0)	37 (68.5%)
Carbapenems				
Imipenem	10 µg	16 (29.6%)	0 (0)	38 (70.4%)
Meropenem	10 µg	12 (22.2%)	0 (0)	42 (77.8%)
B-Lactam combination agents				
Ceftazidime/avibactam	30/20 µg	5 (9.3%)	0 (0)	49 (90.7%)
Ceftolozan/tazobactam	30/10 µg	4 (7.4%)	0 (0)	50 (92.6%)




Fig.2: Multidrug-resistant isolates among *P. aeruginosa* (No. =54).

Biofilm formation:

Out of 54 *P. aeruginosa* isolates; 38 (70.4%) isolates were biofilm producers; 8 isolates (14.8%) were strong biofilm producers, 25 (46.3%) were moderate biofilm producers and 5 (9.3%) were weak biofilm producers, whereas 16 (29.6%) isolates were non biofilm producers (figure 3). The association between the MDR and biofilm formation is statistically highly significant. Out of 38 biofilm forming isolates, 34 (89.5%) were MDR positive while 4 (10.5%) were MDR negative. Regarding 16 non biofilm forming isolates, 7 (43.8%) were MDR positive while 9 (56.2%) were MDR negative (figure 4).




Fig.3: Degrees of biofilm formation of *pseudomonas aeruginosa* isolates (No. =54).




Fig. 4: MDR detection among biofilm forming and non-biofilm forming isolates.

PCR results:

The *lasR* gene was detected in 42 (77.8%) out of 54 *P. aeruginosa* isolates collected, while 12 (22.2%) isolates did not harbor the gene (figure 5&6). *LasR* gene was detected in all biofilm forming isolates (100%) and in only four (25%) of non-biofilmforming isolates. There was highly significant relation between biofilm formation and detection of *lasR* gene (figure 7).




Fig.5: *LasR* gene detection among the 54 studied *P. aeruginosa* isolates.




Fig.6: Agarose gel electrophoresis for *lasR* gene in *P. aeruginosa* isolates.

Lane M: Molecular size marker which gave 10 bands ranging from 100-1000 bp.

Lane 1: Negative control (no bands).

Different strains of *P. aeruginosa* with lasR gene products detected at 130 bp, strains 4 and 10 are negative for lasR gene




Fig.7: LasR gene detection among biofilm forming and non-biofilm forming isolates.

4. DISCUSSION

Bacterial communication via quorum sensing (QS) has been reported to be important in the production of virulence factors, antibiotic sensitivity, and biofilm development. Two QS systems, known as the las and rhl systems have been identified previously in the opportunistic pathogen *P. aeruginosa*^{29,30}.

This study included 54 isolates of *P. aeruginosa* from post-operative wound infected patients admitted in Zagazig University Hospitals, Egypt. In the period from December 2017 till March 2020.

As regards antibiotic susceptibility results in this study, *P. aeruginosa* isolates showed high prevalence of resistance against ceftazidime (74.1%), aztreonam (74.1%) and cefepime (57.4%). The obtained findings are probably due to the wide use of these antibiotics in the hospitals. Hashem et al.³¹ in Egypt reported similar results where 75.5% and 66% of isolates were resistant to ceftazidime and cefepime respectively. Abaza et al.³² in Egypt recorded a high level of resistance to ceftazidime 80%, aztreonam 85.7% and cefepime 79.4%. Another study in Egypt also showed a resistance rate of 68.1% to each of ceftazidime and cefepime and 57.4% to aztreonam³³. In contrast, El-Ageery and Al Otibi³⁴ in Saudi Arabia, reported that 33.3% of *P. aeruginosa* isolates were resistant to ceftazidime and cefepime and 29.6% were resistant to aztreonam. Regarding levofloxacin and amikacin in this study; 46.3% and 31.5% of *P. aeruginosa* isolates were resistant respectively. Elmaraghy et al. in Egypt reported similar results where 46.8% and 36.2% of isolates were resistant to levofloxacin and amikacin respectively³³. Saleem and Bokhari³⁵ in Pakistan also showed similar results, as they reported that 37.2% of *P. aeruginosa* isolates were resistant to amikacin. A higher incidence was detected by

Yekani et al.³⁶ In Iran who reported that 68.02% and 55.48% of their *P. aeruginosa* isolates were resistant to levofloxacin and amikacin respectively. One of the alarming results is the resistance against carbapenems; where 29.6% of isolates were resistant to imipenem and 22.2% were resistant to meropenem. In agreement with our results, Elmaraghy et al.³³ revealed that 14.9% and 38.3% of *P. aeruginosa* isolates were resistant to imipenem and meropenem respectively. A higher incidence was detected by Abaza et al.³² in Egypt who reported that 78.3% and 73.7% of their *P. aeruginosa* isolates were resistant to imipenem and meropenem respectively. The lowest rate of resistance in the current study was to ceftazidime/avibactam and ceftolozane/tazobactam; where only 9.3% and 7.4% of *P. aeruginosa* isolates were resistant respectively. Similarly, Liao et al.³⁷ in Taiwan found 9% and 7% resistance rate to ceftazidime/avibactam and ceftolozane/tazobactam. A lower incidence was detected by Alatoon et al.³⁸ in United Arab Emirates who reported resistance rate of 6% and 3% to ceftazidime/avibactam and ceftolozane/tazobactam respectively. This was an expected finding with ceftazidime/avibactam and ceftolozane/tazobactam, owing to their unavailability in the Egyptian market.

In the present study, the prevalence of MDR isolates were 76% which is slightly higher than the result of Helmy and Kashef³⁹ which were 65.4%. Lower results were recorded by Talaat et al.⁴⁰ and Yekani et al.³⁶ who stated that (59.8%) and (65%) *P. aeruginosa*, respectively, were MDR. Undoubtedly, the rate of MDR *P. aeruginosa* at the Egyptian hospitals is alarming, probably due to the excessive use of a wide range of antibiotics to treat nosocomial infections in hospitals⁴¹. Added to that, the ability of this bacteria to survive for months in hospital environment increases the likelihood of its passage to other patients. Thus awareness, continuous surveillance and antibiotic stewardship to control and prevent the spread of resistant strains have become an indispensable necessity³².

Regarding biofilm results in this study, 38 (70.4%) of *P. aeruginosa* isolates were biofilm producers, 14.8%, 46.3% and 9.3% of isolates were strong, moderate and weak biofilm producers, respectively, whereas, 16 (29.6%) of isolates were non biofilm producers. El-Khashaab et al.⁴² found that among 96 burn and surgical isolates of *P. aeruginosa*, 91.4% showed biofilm formation, among which 25.7%, 40% and 25.7% were strong, moderate and weak biofilm producers respectively. In study done by Dumaru et al.⁴³ biofilm formation was found in 73.6% out of 38 isolates of *P. aeruginosa* of different sources. In contrast, Saha et al.¹⁴ showed biofilm formation in only 29.1% out of 134 *P. aeruginosa* isolates of different sources; 11.9% were strong biofilm producers and 17.2% were moderate biofilm producers.

Yekani et al.³⁶ found that among 50 clinical isolates of *P. aeruginosa* from endotracheal aspirate, 28 of 50 (56%) and 19 of 50 (38%) isolates were biofilm-forming by microtitre and tube methods, respectively. The discrepancy in results between different studies may be attributed to many factors such as the different countries from which the samples were collected, the number and the type of clinical specimens from which the isolates were obtained and also the differences in isolates capability to form biofilm. The primary number of cells that succeeded in adherence and the differences of quality and quantity of autoinducers (quorum sensing signaling molecules) that were produced from each isolate may also play an essential and an important role⁴⁴.

In the present study we found a significant correlation between MDR and biofilm formation, where 89.5% of biofilm forming isolates were MDR. So the strains capable of forming biofilms were more frequently observed to be an MDR phenotype. These findings come in accordance with other studies which reported the same results^{36, 14, 45}. This proposes that physiological features particular to biofilm formation; efflux pumps expression, pharmacologic

characteristics, B- lactamase and amino-transferase production might play a role in improve biofilm antimicrobial resistance. However, biofilm-producing bacteria are 10 to 1000 times more resistant to antimicrobial agents than the planktonic cell ⁴⁶. This can be one explanation as to why there is a higher failure rate in the eradication of biofilm- related infections.

The lasR gene was detected in 42 (77.8%) out of 54 *P. aeruginosa* isolates collected, while only 12 (22.2%) isolates did not harbor the gene. LasR gene was detected in all biofilm forming isolates (100%) and in only four (25%) of non biofilm forming isolates. There was highly significant relation between biofilm formation and detection of lasR gene. Our results showed that 4 biofilm deficient isolates were lasR QS gene proficient. This finding is in concordance with Schaber et al.²⁶, who stated that three factors (flagellar-mediated swimming motility, pilus-mediated twitching motility and QS) are considered important for biofilm formation in *P. aeruginosa*. Thereby, in the present study, it could be related to our isolates might deficient in either or both remaining factors. Moreover, the isolates may be deficient in other genes rather lasR gene, such as the lasI, rhlR and rhlI genes. There is proportion of isolates (12/54) that were deficient in both lasR and biofilm, whereas, these isolates causing clinical wound infection. This observation was explained by several other clinical studies which showed that the loss of any single virulence factor appeared to be compensated by other virulence factors during infection⁴⁷. Further, Dénervaud et al.⁴⁸ concluded that there were *P. aeruginosa* strains defected in the production of both signaling molecules and extracellular virulence factors and inducing infection because of uncharacterized virulence factors other than known ones.

In conclusion, our results indicate that Postoperative wound infection may serve as a reservoir for multidrug resistant biofilm forming *P. aeruginosa* and that the QS lasR gene is strongly associated with biofilm formation and could therefore be used as a as a useful diagnostic marker for biofilm producing *P. aeruginosa* strains isolated from infected wounds. Further studies regarding the molecular mechanisms involved in biofilm formation including studying expression and sequencing of QS genes will give a better understanding of the pathogenesis of biofilm formation which will ultimately lead to novel strategies for controlling recalcitrant biofilms.

REFERENCES

1. **Bastola R, Parajuli P, Neupane A, Paudel A. (2017):** Surgical site infections: distribution studies of sample, outcome and antimicrobial susceptibility testing. *J Med Microb Diagn*; 6(1) 252.
2. **Badia JM, Casey AL, Petrosillo N, Hudson PM, Mitchell SA, Crosby C. (2017):** Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. *J Hosp Infect*; 96(1): 1-15.
3. **Olowo-Okere A, Ibrahim YKE, Olayinka BO, Ehinmidu JO. (2019):** Epidemiology of surgical site infections in Nigeria: a systematic review and meta-analysis. *Nigerian Postgraduate Medical Journal*; 26(3):143-151.
4. **Asres GS, Legese MH, Woldearegay GM. (2017):** Prevalence of multidrug resistant bacteria in postoperative wound infections ay Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. *Arch Med*; 9(4):12.
5. **Rocha AJ, Barsottini MRO, Rocha RR, Laurindo MV, de Moraes FLL, da Rocha SL. (2019):** *Pseudomonas aeruginosa*: virulence factors and antibiotic resistance genes. *Brazilian Archives of Biology and Technology*; 62: 1-15.

6. **Römbling U, Balsalobre C. (2012):** Biofilm infections, their resilience to therapy and innovative treatment strategies. *Journal of Internal Medicine*; 272(6): 541-561.
7. **Boyle KP, Heilmann S, Ditmarsch DV, Xavier JB. (2013):** Exploiting social evolution in biofilms. *Current Opinion in Microbiology*; 16:1-6.
8. **Al Sanjee S, Hassan M, Manchur MA. (2018):** In vitro biofilm formation by multidrug resistant clinical isolates of *Pseudomonas aeruginosa*. *Asian J Med Biol Res*; 4(1): 105-116.
9. **Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies DG. (2002):***Pseudomonas aeruginosa* displays multiple phenotypes during development as a biofilm. *J Bacteriol*; 184: 1140-1154.
10. **O'Toole G, Kolter R. (1998):** Flagellar and twitching motility are necessary for *Pseudomonas aeruginosa* biofilm development. *Mol Microbiol*; 30: 295-304.
11. **Donlan RM, Costerton JW. (2002):** Biofilms: survival mechanisms of clinically relevant microorganisms. *Clinical Microbiology Reviews*; 15: 167-193.
12. **Prince AS. (2002):** Biofilms, antimicrobial resistance, and airway infection. *N Engl J Med*; 347: 1110–1111.
13. **Stickler DJ. (2002):** Susceptibility of antibiotic resistant gram negative bacteria to biocides: a perspective from the study of catheter biofilms. *J Appl Microbiol*; 92(Suppl): 163S–170S.
14. **Saha S, Devi KM, Damrolien S, Devi KS, Krossnunpui Sharma KT. (2018):** Biofilm production and its correlation with antibiotic resistance pattern among clinical isolates of *Pseudomonas aeruginosa* in a tertiary care hospital in north-east India. *International Journal of Advances in Medicine*; 5(4): 964-968.
15. **Rumbaugh KP, Griswold JA, Hamood AN. (2000):** The role of quorum sensing in the in vivo virulence of *Pseudomonas aeruginosa*. *Microbes Infect*; 2: 1721–1731.
16. **Venturi V. (2006):** Regulation of quorum sensing in *Pseudomonas*. *FEMS Microbiol Rev*; 30: 274–291.
17. **Pesci EC, Pearson JP, Seed PC, Iglewski BH. (1997):** Regulation of las and rhl quorum sensing in *Pseudomonas aeruginosa*. *J Bacteriol*; 179: 3127-3132.
18. **Latifi A, Foglino M, Tanaka T, Williams P, Lazdunski A. (1996):** A hierarchical quorum sensing cascade in *Pseudomonas aeruginosa* links the transcriptional activators LasR and VsmR to expression of the stationary phase sigma factor RpoS. *Mol Microbiol*; 21: 1137-1146.
19. **Schuster M, Greenberg EP. (2006):** A network of networks: quorum-sensing gene regulation in *Pseudomonas aeruginosa*. *Int J Med Microbiol*; 296: 73-81.
20. **Pesci EC, Milbank JB, Pearson JP, McKnight S, Kende AS, Greenberg EP, et al. (1999):** Quinolone signaling in the cell-to-cell communication system of *Pseudomonas aeruginosa*. *Proc Natl Acad Sci USA*; 96: 11229–11234.
21. **De Kievit TR, Gillis R, Marx S, Brown C, Iglewski BH. (2001):** Quorum-sensing genes in *Pseudomonas aeruginosa* biofilms: their role and expression patterns. *Appl Environ Microbiol*; 67: 1865-1873.
22. **Collee J, Miles R, Watt B. (1996):** Tests for identification of bacteria. In: Mackie and Mc Carteny Practical Medical Microbiology. Collee JG, Fraser AG, Marmion BP, Simmons A (eds). Churchill Livingstone. 14th edition; chap 7: 131-150.
23. **Clinical and Laboratory Standards Institute (CLSI) (2019):** Performance standards for antimicrobial susceptibility testing; 29th ed. CLSI supplement M100. Wayne, PA.

24. **Christensen GD, Simpson WA, Younger JJ, Baddour LM, Barrett FF, Melton DM, et al. (1985):** Adherence of coagulase negative *Staphylococci* to plastic tissue culture plates: a quantitative model for the adherence of *Staphylococci* to medical devices. *Journal of Clinical Microbiology*; 22(6): 996-1006.
25. **Stepanovic S, Vuković D, Hola V, Di Bonaventura G, Djukić S, Cirković I, et al. (2007):** Quantification of biofilm in microtiter plates overview of testing conditions and practical recommendations for assessment of biofilm production by *Staphylococci*. *APMIS*; 115(8):891-899.
26. **Schaber JA, Carty NL, McDonald NA, Graham ED, Cheluvappa R, Griswold JA, et al. (2004):** Analysis of quorum sensing-deficient clinical isolates of *Pseudomonas aeruginosa*. *J Med Microbiol*; 53: 841-853.
27. **Senturk S, Ulusoy S, Bosgelmez-Tinaz G, Yagci A. (2012):** Quorum sensing and virulence of *Pseudomonas aeruginosa* during urinary tract infections. *Journal of Infection in Developing Countries*; 6(6): 501-507.
28. **Zhu H, Bandara R, Conibear TCR, Thuruthyil SJ, Rice SA, Kjelleberg S, et al. (2004):** *Pseudomonas aeruginosa* with lasI quorum-sensing deficiency during corneal infection. *Investigative Ophthalmology and Visual Journal*; 45(6): 1897-1903.
29. **Li Y, Qu HP, Liu JL, Wan HY. (2014):** Correlation between group behavior and quorum sensing in *Pseudomonas aeruginosa* isolated from patients with hospital-acquired pneumonia. *J Thorac Dis*; 6(6): 810-817.
30. **Wang Y, Gao L, Rao X, Wang J, Yu H, Jiang J, et al. (2018):** Characterization of lasR- deficient clinical isolates of *Pseudomonas aeruginosa*. *Scientific Reports*; 8:13344.
31. **Hashem H, Hanora A, Abdalla S, Shawky A, Saad A. (2016):** Carbapenem susceptibility and multidrug-resistance *Pseudomonas aeruginosa* isolates in Egypt. *Jundishapur Journal of Microbiology*; 9(11): e30257.
32. **Abaza AF, EL Shazly SA, Selim HS, Aly GS. (2017):** Metallo-beta-lactamase producing *Pseudomonas aeruginosa* in a healthcare setting in Alexandria, Egypt. *Pol J Microbiol*; 66(3): 297-308.
33. **Elmaraghy N, Abbadi S, Elhadidi G, Hashem A, Yousef A. (2019):** Virulence genes in *Pseudomonas aeruginosa* strains isolated at Suez Canal University Hospitals with respect to the site of infection and antimicrobial resistance. *International Journal of Clinical Microbiology and Biochemical Technology*; 2: 008-019.
34. **El-Ageery SM, Al Otibi AAM. (2016):** Phenotypic and genotypic characterization of *Pseudomonas aeruginosa* isolates from burn patients. *Egyptian Journal of Medical Microbiology*, 25(1): 53-60.
35. **Saleem S, Bokhari H. (2019):** Resistance profile of genetically distinct clinical *Pseudomonas aeruginosa* isolates from public hospitals in central Pakistan. *Journal of Infection and Public Health*; 13(4), 598–605.
36. **Yekani M, Memar MY, Alizadeh N, Safaei N, Ghotaslou R. (2017):** Antibiotic resistance patterns of biofilm-forming *Pseudomonas aeruginosa* isolates from mechanically ventilated patients. *International Journal of Scientific Study*; 5(5): 84-88.
37. **Liao C, Lee N, Tang H, Lee SS, Lin C, Lu P, et al. (2019):** Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* isolated from intensive care units in Taiwan: results from the surveillance of multicenter antimicrobial resistance in Taiwan in 2016. *Infection and Drug Resistance*; 12: 545–552.

38. **Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona L, et al. (2017):** Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug- resistant isolates of *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. International Journal of Infectious Diseases; 62: 39-43.
39. **Helmy OM, Kashef MT. (2017):** Different phenotypic and molecular mechanisms associated with multidrug resistant in gram-negative clinical isolates from Egypt. Infection and Drug Resistance; 10: 479-498 .
40. **Talaat M, EL-Shokry M, EL-Kholy J, Ismail G, Kotb S, Hafez S, et al. (2016):** National surveillance of health care-associated infections in Egypt: developing a sustainable program in a resource-limited country. Am J Infect Control; 44(11): 1296-1301.
41. **Abbas HA, EL-Ganiny AM, Kamel HA. (2018):** Phenotypic and genotypic detection of antibiotic resistance of *Pseudomonas aeruginosa* isolated from urinary tract infections. African Health Sciences; 18(1): 11-21.
42. **El-Khashaab TH, Erfan DM, Kamal A, El-Moussely LM, Ismail DK. (2016):** *Pseudomonas aeruginosa* biofilm formation and quorum sensing lasR gene in patients with wound infection. Egyptian Journal of Medical Microbiology; 25(1): 101-108.
43. **Dumaru R, Baral R, Shrestha LB. (2019):** Study of biofilm formation and antibiotic resistance pattern of gram-negative bacilli among the clinical isolates at BPKIHS, Dharan. BMC Research Notes; 12-38.
44. **Beenken KE, Mrak LN, Griffin LM, Zielinska AK, Shaw LN, Rice KC, et al. (2010):** Epistatic relationships between sarA and agr in *Staphylococcus aureus* biofilm formation. Plos. One; 5(5): e 10790.
45. **Karami P, Mohajeri P, Mashouf RY, Karami M, Yaghoobi MH, Dastan D, et al. (2019):** Molecular characterization of clinical and environmental *Pseudomonas aeruginosa* isolated in a burn center. Saudi Journal of Biological Sciences; 26:1731-1736.
46. **Abidi SH, Sherwani SK, Siddiqui TR, Bashir A, Kazmi SU. (2013):** Drug resistance profile and biofilm forming potential of *Pseudomonas aeruginosa* isolated from contact lenses in Karachi-Pakistan. BMC Ophthalmology; 13(1): 57.
47. **Taha SA, Elhaig MM, Youssef N, Badran, DI (2014):** The lasR quorum sensing gene in clinical isolates of *Pseudomonas aeruginosa* and relationship with biofilm formation. Journal of Molecular Diagnosis and Vaccines; 12: 63-68.
48. **Dénervaud V, TuQuoc P, Blanc D, Favre-Bonte S, Krishnapillai V, Reimmann C, et al. (2004):** Characterization of cell-to-cell signaling deficient *Pseudomonas aeruginosa* strains colonizing intubated patients. J Clin Microbiol; 42: 554-562.